L

Lineage Cell Therapeutics Inc
F:BT3

Watchlist Manager
Lineage Cell Therapeutics Inc
F:BT3
Watchlist
Price: 1.43 EUR 2.14% Market Closed
Market Cap: 269.9m EUR

Wall Street
Price Targets

BT3 Price Targets Summary
Lineage Cell Therapeutics Inc

Wall Street analysts forecast BT3 stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BT3 is 3.44 EUR with a low forecast of 1.64 EUR and a high forecast of 7.66 EUR.

Lowest
Price Target
1.64 EUR
14% Upside
Average
Price Target
3.44 EUR
141% Upside
Highest
Price Target
7.66 EUR
436% Upside
Lineage Cell Therapeutics Inc Competitors:
Price Targets
302440
SK Bioscience Co Ltd
22% Downside
002252
Shanghai RAAS Blood Products Co Ltd
11% Upside
CHRS
Coherus BioSciences Inc
331% Upside
6855
Ascentage Pharma Group International
90% Upside
CDNA
CareDx Inc
19% Upside
RNA
Avidity Biosciences Inc
3% Upside
XNCR
Xencor Inc
87% Upside
SPRB
Spruce Biosciences Inc
154% Upside

Revenue
Forecast

Revenue Estimate
Lineage Cell Therapeutics Inc

For the last 13 years the compound annual growth rate for Lineage Cell Therapeutics Inc's revenue is 6%. The projected CAGR for the next 4 years is 58%.

6%
Past Growth
58%
Estimated Growth
Estimates Accuracy
1%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Lineage Cell Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Net Income
Forecast

Net Income Estimate
Lineage Cell Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-38%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is BT3's stock price target?
Price Target
3.44 EUR

According to Wall Street analysts, the average 1-year price target for BT3 is 3.44 EUR with a low forecast of 1.64 EUR and a high forecast of 7.66 EUR.

What is Lineage Cell Therapeutics Inc's Revenue forecast?
Projected CAGR
58%

For the last 13 years the compound annual growth rate for Lineage Cell Therapeutics Inc's revenue is 6%. The projected CAGR for the next 4 years is 58%.

Back to Top